Document is current
Any future updates will be listed below
-
Authors
Nakanishi, Hiroshi
Kurima, Kiyoto
Pan, Bifeng https://orcid.org/0000-0001-9746-3420
Wangemann, Philine
Fitzgerald, Tracy S.
Géléoc, Gwenaëlle S.
Holt, Jeffrey R.
Griffith, Andrew J.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Deafness and Other Communication Disorders (Z01-DC000080)
U.S. Department of Health & Human Services | NIH | National Institute on Deafness and Other Communication Disorders (R01-DC013521)
U.S. Department of Health & Human Services | NIH | National Institute on Deafness and Other Communication Disorders (Z01-DC000060)
- License Information
-
More Information
Article History
Received: 5 April 2018
Accepted: 3 July 2018
First Online: 14 August 2018
Competing Interests
: K.K. and A.J.G. hold patents related to Tmc1 and Tmc2 and receive royalties from EMD Millipore for anti-Tmc1 antibodies. G.S.G. and J.R.H. hold patents related to Tmc1 gene therapy. J.R.H. is a scientific advisor for Frequency Therapeutics and Applied Genetic Technologies Corporation.
